Ceribell: Vegas Takes

研报英文原文证据摘录

Ceribell: Vegas Takes

Opportunities for continued utilization improvement

CBLL’s active account base is only 30% penetrated. Top accounts use the Ceribell

system at ~3x the rate of the average account. The key differentiators observed in those

accounts include: 1) coverage across all departments (ICUs, EDs, step-down units, and

floors), 2) a coherent cross-department patient workflow, 3) well-trained physician and

nursing staff, including overnight shifts, and 4) protocolized use for specific patient

populations such as post-cardiac arrest patients, where AHA guidelines call for prompt

EEG monitoring. There also is still room for additional utilization in the top accounts and

these accounts are easier opportunities to bring in new indications. New account

utilization is modestly below the average (small dilutive effect), but CBLL invests in

high-quality launches to establish best practices from day one, which tend to be sticky.

Neonate in full commercial launch

Feedback from neonate has been very positive which is why CBLL announced full

commercialization this qtr, towards the optimistic end of the internal timeline. CBLL

noted a benefit of the neonate launch is not needing to explain the difference of partial

montage vs full montage, which was a hurdle in the adult seizure launch but not neonate

given neonate is full montage. CBLL also highlighted that clinicians caring for neonates

place a particularly high emphasis on neurological outcomes. The DRG for neonate is

higher than adult because these patients stay in the ICU for much longer. If hospitals can

avoid patient transfer with access to EEG, they can keep these patients which benefits

hospital economics. CBLL has just started messaging the neonate product to the 200

NICUs in its installed base.